ACADIA Pharmaceuticals

ISIN US0042251084

 | 

WKN 603035

Market cap (in EUR)
3,749 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overzicht

Beschrijving

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Toon meer Toon minder
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 3,749 m
WPA, EUR 1.41
KBV 4.8
K/W 16.8
Dividendrendement 0.00%

Income statement (2024)

Omzet, EUR 885 m
Netto-inkomen, EUR 209 m
Winstmarge 23.64%

What ETF is ACADIA Pharmaceuticals in?

There are 5 ETFs which contain ACADIA Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of ACADIA Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.33%
Equity
United States
Health Care
Biotech
46
iShares S&P SmallCap 600 UCITS ETF 0.23%
Equity
United States
Small Cap
1,920
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
490
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
25
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.05%
Equity
United States
Small Cap
187
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.

Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.